The beneficial effect of positive treatment expectations on pharmacological migraine prophylaxis.
Journal
Pain
ISSN: 1872-6623
Titre abrégé: Pain
Pays: United States
ID NLM: 7508686
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
received:
05
01
2021
accepted:
07
05
2021
pubmed:
20
5
2021
medline:
24
3
2022
entrez:
19
5
2021
Statut:
ppublish
Résumé
Migraine is one of the leading causes of years lived with disability and considered to be a major global health concern. Pharmacological preventive treatment often causes side effects that limit the adherence to longer-term treatment regimens. Both experimental and clinical evidence suggests that positive expectations can modulate pain and analgesic treatment effects. However, the role of expectations in migraine prophylactic treatment has not systematically been investigated. Here, we examined the influence of treatment expectation before commencing pharmacological preventive treatment on its efficacy and tolerability in N = 134 episodic (30%) and chronic migraine (70%) patients in a prospective, longitudinal observational study over the course of 6 months. The migraine prophylaxis reduced the number of headache and migraine days with acceptable tolerability. Positive treatment expectation was associated with a generally lower number of headache and migraine days and a stronger reduction in headache days over the course of the treatment in chronic but not in episodic migraine patients. Moreover, patients with prior treatment showed a stronger reduction in headache days with higher expectation as compared to patients without prior experience. Our results underscore the relevance of further exploring the role of treatment expectation and its systematic modulation in patients with migraine and other pain conditions.
Identifiants
pubmed: 34010939
doi: 10.1097/j.pain.0000000000002341
pii: 00006396-202202000-00030
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e319-e327Informations de copyright
Copyright © 2021 International Association for the Study of Pain.
Références
Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. PAIN 2009;146:261–9.
Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Smith J. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020;40:241–54.
Atlas LY, Wager TD. How expectations shape pain. Neurosci Lett 2012;520:140–8.
Beecher HK. The powerful placebo. J Am Med Assoc 1955;159:1602–6.
Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, Ploner M, Tracey I. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Translation Med 2011;3:70ra14.
Bingel U. Avoiding nocebo effects to optimize treatment outcome. JAMA 2014;312:693–4.
Bingel U. Placebo 2.0: the impact of expectations on analgesic treatment outcome. PAIN 2020;161(suppl 1):S48–s56.
Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, Goadsby PJ, Lipton RB. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301–15.
Buse D, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010;81:428–32.
Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, Lipton R. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache 2012;52:3–17.
Charron J, Rainville P, Marchand S. Direct comparison of placebo effects on clinical and experimental pain. Clin J Pain 2006;22:204–11.
Colloca L, Barsky AJ. Placebo and nocebo effects. N Engl J Med 2020;382:554–61.
Colloca L, Klinger R, Flor H, Bingel U. Placebo analgesia: psychological and neurobiological mechanisms. PAIN 2013;154:511–14.
Cormier S, Lavigne GL, Choiniere M, Rainville P. Expectations predict chronic pain treatment outcomes. PAIN 2016;157:329–38.
Devilly GJ, Borkovec TD. Psychometric properties of the Credibility/Expectancy Questionnaire. J Behav Ther Exp Psychiatry 2000;31:73–86.
Diener HC, Schorn CF, Bingel U, Dodick DW. The importance of placebo in headache research. Cephalalgia 2008;28:1003–11.
Diener HC, Gaul C, Kropp P. Therapie der Migräneattacke und Prophylaxe der Migräne. Nervenheilkunde 2018;37:689–715.
Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 2013;12:191–204.
Hanson LL, Ahmed Z, Katz BJ, Warner JEA, Crum AV, Zhang Y, Zhang Y, Baggaley S, Pippitt K, Cortez MM, Digre KB. Patients with migraine have substantial reductions in measures of visual quality of life. Headache 2018;58:1007–13.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1–211.
Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, Clarke CE, Sinclair AJ. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open 2019;9:e027953.
Hess AS, Abd-Elsayed A. Observational studies: uses and limitations. In: Abd-Elsayed A, ed. Pain: A Review Guide. Cham: Springer International Publishing, 2019; 123–5.
Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One 2015;10:e0130733.
Jenkinson C, Layte R, Jenkinson D, Lawrence K, Petersen S, Paice C, Stradling J. A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies? J Public Health 1997;19:179–86.
Johnson PC. Extension of Nakagawa & Schielzeth's R2GLMM to random slopes models. Methods Ecol Evol 2014;5:944–6.
Jospe M. The placebo effect in healing. Lexington, MA: Lexington Books, 1978, 170 pp.
Kam-Hansen S, Jakubowski M, Kelley JM, Kirsch I, Hoaglin DC, Kaptchuk TJ, Burstein R. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Translation Med 2014;6:218ra215.
Kaptchuk TJ, Kelley JM, Deykin A, Wayne PM, Lasagna LC, Epstein IO, Kirsch I, Wechsler ME. Do “placebo responders” exist? Contemp Clin Trials 2008;29:587–95.
Kleine-Borgmann J, Schmidt K, Hellmann A, Bingel U. Effects of open-label placebo on pain, functional disability, and spine mobility in patients with chronic back pain: a randomized controlled trial. PAIN 2019;160:2891–7.
Kosek E, Rosen A, Carville S, Choy E, Gracely RH, Marcus H, Petzke F, Ingvar M, Jensen KB. Lower placebo responses after long-term exposure to fibromyalgia pain. J Pain 2017;18:835–43.
Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlöf CG, Dowson A, Tepper S. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 2003;12:963–74.
Kube T, Glombiewski JA, Rief W. Using different expectation mechanisms to optimize treatment of patients with medical conditions: a systematic review. Psychosomatic Med 2018;80:535–43.
Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet 1978;2:654–7.
Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache 2015;55(suppl 2):103–22; quiz 123-106.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343–9.
Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020;94:e1365–77.
Meissner K, Fassler M, Rucker G, Kleijnen J, Hrobjartsson A, Schneider A, Antes G, Linde K. Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis. JAMA Intern Med 2013;173:1941–51.
Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 2011;31:550–61.
Nakagawa S, Schielzeth H. A general and simple method for obtaining R2 from generalized linear mixed‐effects models. Methods Ecol Evol 2013;4:133–42.
Nilges P, Essau C. Die Depressions-Angst-Stress-Skalen: der DASS–ein Screeningverfahren nicht nur für Schmerzpatienten (Originalien). Der Schmerz 2015;29:649–57.
Peres MFP, Oliveira AB, Mercante JP, Kamei HH, Tobo PR, Rozen TD, Levin M, Buse DC, Lucchetti G. Optimism, pessimism, and migraine: a cross-sectional, population-based study. Headache 2019;59:205–14.
Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991;31:295–9.
Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. PAIN 1999;83:147–56.
Price DD, Fillingim RB, Robinson ME. Placebo analgesia: friend or foe? Curr Rheumatol Rep 2006;8:418–24.
RCoreTeam R. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. Available at: https://wwwR-projectorg/2019 .
Rief W, Glombiewski J, Barsky A. Generic Assessment of Side Effects: GASE. Bern: Verlag Hans Huber, 2009.
Schmitz J, Müller M, Stork J, Eichler I, Zöllner C, Flor H, Klinger R. Positive treatment expectancies reduce clinical pain and perceived limitations in movement ability despite increased experimental pain: a randomized controlled trial on sham opioid infusion in patients with chronic back pain. Psychother Psychosom 2019;88:203–14.
Schulte D. Messung der Therapieerwartung und Therapieevaluation von Patienten (PATHEV). Z für Klinische Psychol Psychotherapie 2005;34:176–87.
Speciali JG, Peres M, Bigal ME. Migraine treatment and placebo effect. Expert Rev Neurotherapeutics 2010;10:413–19.
Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, Ansha MG, Barac A, Bensenor IM, Doan LP, Edessa D, Endres M, Foreman KJ, Gankpe FG, Gopalkrishna G, Goulart AC, Gupta R, Hankey GJ, Hay SI, Hegazy MI, Hilawe EH, Kasaeian A, Kassa DH, Khalil I, Khang YH, Khubchandan J, Kim YJ, Kokubo Y, Mohammed MA, Moradi-Lakeh M, Nguyen HLT, Nirayo YL, Qorbani M, Ranta A, Roba KT, Safiri S, Santos IS, Satpathy M, Sawhney M, Shiferaw MS, Shiue I, Smith M, Szoeke CEI, Truong NT, Venketasubramanian N. Weldegwergs Kg, Westerman R, Wijeratne T, Tran BX, Yonemoto N, Feigin VL, Vos T, Murray CJL. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17:954–76.
Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 2018;38:815–32.
Teunis T. Botulinum toxin versus placebo: a meta-analysis of prophylactic treatment for migraine. Plast Reconstr Surg 2019;144:1119e–20e.
The M. American Headache Society Position Statement on integrating new migraine treatments into clinical practice. Headache 2019;59:1–18.
Tinnermann A, Geuter S, Sprenger C, Finsterbusch J, Buchel C. Interactions between brain and spinal cord mediate value effects in nocebo hyperalgesia. Science 2017;358:105–8.
Twisk J, de Vente W. Attrition in longitudinal studies. How to deal with missing data. J Clin Epidemiol 2002;55:329–37.
Vase L, Petersen GL, Riley JL III, Price DD. Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007. PAIN 2009;145:36–44.
Vase L, Vollert J, Finnerup NB, Miao X, Atkinson G, Marshall S, Nemeth R, Lange B, Liss C, Price DD, Maier C, Jensen TS, Segerdahl M. Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials. PAIN 2015;156:1795–802.
Visser WH, Winner P, Strohmaier K, Klipfel M, Peng Y, McCarroll K, Cady R, Lewis D, Nett R. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache 2004;44:891–9.
Wendt L, Albring A, Benson S, Engler H, Engler A, Hinney A, Rief W, Witzke O, Schedlowski M. Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses. PLoS One 2014;9:e107665.
Wirtz MA, Morfeld M, Glaesmer H, Brähler E. Normierung des SF-12 Version 2.0 zur Messung der gesundheitsbezogenen Lebensqualität in einer deutschen bevölkerungsrepräsentativen Stichprobe. Diagnostica 2018;64:215–26.
Zunhammer M, Ploner M, Engelbrecht C, Bock J, Kessner SS, Bingel U. The effects of treatment failure generalize across different routes of drug administration. Sci Translation Med 2017;9:eaal2999.